Nivolumab

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Giovedì, Maggio 9, 2024
Immunotherapy, FDA, Society, Nivolumab, Research, National Cancer Institute, Bevacizumab, PD-1, ASCO, Journal, Therapy, Liver, Patient, NCI, SITC, RCC, AACR, Kidney cancer, FFA, Growth, HCC, Pharmaceutical industry

BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2024, and provided a corporate update.
  • These data further support the clinical benefit observed in the TPST-1120 Phase 1 data presented in an oral presentation at ASCO 2022.
  • Tempest ended the quarter with $32.3 million in cash and cash equivalents, compared to $39.2 million on December 31, 2023.
  • Based on its current cash and operating plan, Tempest expects to have sufficient resources to fund operations into the second quarter of 2025.

Immunocore reports first quarter financial results and provides a business update

Retrieved on: 
Mercoledì, Maggio 8, 2024
CTA, Total, Research, HLA, IND, ASCO, Research and development, BMY, Annual report, Drug, Autoimmune disease, APC, HIV, Bristol Myers Squibb, TCR, Autoimmunity, Infection, PRAME, Treatment, EMA, GMP, Clinical trial, Investigational New Drug, Platinum, ImmTAC, Nivolumab, Security (finance), Form 10-Q, Half-life, Patient, Immune system, Pharmaceutical industry

& ROCKVILLE, Md., US, May 8, 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2024 and provided a business update.

Key Points: 
  • & ROCKVILLE, Md., US, May 8, 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2024 and provided a business update.
  • Net loss for the first quarter of 2024 was $24.4 million compared to a net loss of $19.4 million in the same period in 2023.
  • The first quarter basic and diluted loss per share was $0.49, compared to $0.40 for the first quarter of 2023.
  • This includes net cash proceeds of $390.2 million from the Company’s offering of convertible notes in February 2024.

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
Lunedì, Maggio 6, 2024
FDA, Total, ITK, Research, PTCL, PR, Doctor of Philosophy, Webcast, Fungal infection, Atopic dermatitis, RCC, Lymphoma, Vanderbilt University Medical Center, Lung cancer, Conference call, Kidney cancer, Conference, CRS, Peripheral, Assistant, PRS, NSCLC, Patient, Safety, Pembrolizumab, Modified, CTCL, Time management, Clinical trial, Division, Sale, A2A, Adenosine, HNSCC, T-cell lymphoma, Nivolumab, Ipilimumab, B-cell lymphoma, Disease, ALCL, Physician, Head, PTCL-NOS, Pharmaceutical industry

BURLINGAME, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024.
  • Corvus anticipates initiating a registrational Phase 3 clinical trial of soquelitinib in patients with relapsed PTCL in the third quarter of 2024.
  • Corvus will host a conference call and webcast today, Monday, May 6, 2024, at 4:30 p.m.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the first quarter 2024 financial results.

Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates

Retrieved on: 
Mercoledì, Maggio 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, FDA, Pfizer, Investment, NMPA, Pancreatic cancer, Schizophrenia, ASCO, HKT, Ovarian cancer, AstraZeneca, ELCC, Lung cancer, METIS, Food, CER, Genmab, Roche, GIST, CABP, Psoriasis, BLA, Bristol Myers Squibb, NSCLC, Psychosis, HKEX, NRDL, Safety, SCLC, Research and development, ABSSSI, Marketing, BMS, Clinical trial, Bronchopneumonia, GMG, TED, KarXT, Nivolumab, NDA, Stromal cell, MAA, Carcinoma, Administration, ADS, Patient, Society, Annual general meeting, Sanofi, Growth, Pharmaceutical industry

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2024, along with recent product highlights and corporate updates.

Key Points: 
  • Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2024, along with recent product highlights and corporate updates.
  • “Our first quarter results demonstrate strong commercial execution and pipeline progress across our potential first- and best-in-class product portfolio,” said Dr. Samantha Du, Founder, Chairperson, and Chief Executive Officer of Zai Lab.
  • In March 2024, Zai Lab presented findings from preclinical studies highlighting the therapeutic potential of ZL-1310 at the European Lung Cancer Congress (ELCC) 2024.
  • Zai Lab to initiate a global Phase 2 study in mild-to-moderate chronic plaque psoriasis in the second quarter of 2024.

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...

Retrieved on: 
Lunedì, Maggio 6, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Type 2, PFS, Cancer, BMY, Nivolumab, MSI-H, Ipilimumab, Progression-free survival, Immunotherapy, ASCO, Checkmate, Patient, Society, EMA, Bristol Myers Squibb, European Medicines Agency, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).
  • The EMA’s validation of the application confirms the submission is complete and begins the EMA’s centralized review process.
  • The study is ongoing to assess the other dual primary endpoint of PFS in patients receiving Opdivo plus Yervoy compared to Opdivo alone, as well as secondary endpoints.
  • Bristol Myers Squibb thanks the patients and investigators involved in the CheckMate -8HW clinical trial.

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Retrieved on: 
Giovedì, Aprile 25, 2024
PFS, Efficacy, Safety, DCR, Risk, Nivolumab, Randomness, SOC, Drug resistance, Death, CM24, Tumor microenvironment, OS, PD-1, PDAC, ASCO, Cancer, Patient, Society, CA19-9, Interim, BMS, Neoplasm, Bristol Myers Squibb, Annual general meeting, Pharmacodynamics, Escape Room, Pharmaceutical industry

REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that interim results from its randomized, controlled, open label, multicenter Phase 2 study of CM24, a first in class immune checkpoint inhibitor, for the treatment of pancreatic ductal adenocarcinoma (PDAC), have been selected as late-breaking abstract poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting which will take place on May 31 – June 4, 2024 in Chicago, Illinois.

Key Points: 
  • The primary endpoint of the study is overall survival (OS), with progression free survival (PFS) and objective response rate (ORR) as secondary endpoints.
  • The study was designed as Bayesian to evaluate the potential benefit of the experimental arm vs SoC and is not powered for hypothesis testing.
  • Approximately 60 patients have been enrolled in the randomized study in 18 centers in the U.S., Spain and Israel.
  • “We are honored to be selected by the ASCO committee with our late breaking abstract poster presentation and are looking forward to presenting our interim results from our randomized Phase 2 CM24 study at the ASCO 2024 annual meeting.” stated Gil Efron, Chief Executive Officer of Purple Biotech.

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Mercoledì, Aprile 24, 2024
ASCO, CAB, Therapy, Society, SAN, Nivolumab, Conditional, Pharmaceutical industry

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.

Key Points: 
  • SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.
  • Phase 1 study of BA3071, an anti-CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors

Immunocore announces upcoming presentation and posters at ASCO 2024

Retrieved on: 
Mercoledì, Aprile 24, 2024
ImmTAC, Cancer, Nivolumab, Ipilimumab, Infection, Webcast, Immunocore, PRAME, ASCO, Patient, Society, Annual general meeting, Communications satellite

ET

Key Points: 
  • ET
    Session: Poster Session – Melanoma/Skin Cancers, Saturday 1 June 2024, 1:30-4:30 p.m. CT / 12:30-3:30 p.m.
  • ET
    Session: Poster Session – Melanoma/Skin Cancers, Saturday 1 June 2024, 1:30-4:30 p.m. CT / 12:30-3:30 p.m.
  • ET
    Session: Poster Session – Melanoma/Skin Cancers, Saturday 1 June 2024, 1:30-4:30 p.m. CT / 12:30-3:30 p.m.
  • ET
    Session: Poster Session – Melanoma/Skin Cancers, Saturday 1 June 2024, 1:30-4:30 p.m. CT / 12:30-3:30 p.m.

Enterome Announces Successful Completion of Phase 2 ROSALIE Study of EO2401 in Recurrent Glioblastoma

Retrieved on: 
Mercoledì, Aprile 17, 2024
Society, Nature, SNO, Nivolumab, Service provider, Survival rate, Immunotherapy, Standard of care, Bevacizumab, Glioblastoma, Immune tolerance, Weapon, Patient, Peptide, Inflammation, Immune system, Neoplasm, Vaccine

PARIS, April 17, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced database lock of its Phase 2 study of EO2401, in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab), for the treatment of patients with recurrent glioblastoma (EOGBM1-18/ROSALIE trial).

Key Points: 
  • A total of 100 patients have been enrolled in ROSALIE, an international, open-label Phase 1/2 trial of EO2401 an innovative, off-the-shelf immunotherapy derived from Enterome’s oncomimicry platform.
  • Jan Fagerberg, Chief Medical Officer of Enterome, said: “The achievement of the first trial evaluating EO2401 represents a major milestone for Enterome.
  • The ROSALIE study represents the first demonstration of OncoMimics™ immunotherapies’ ability to overcome immune tolerance, promising new avenues for targeting cancer cells.
  • I also would like to thank patients, their families, and investigators whose dedication made this groundbreaking study possible."

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

Retrieved on: 
Giovedì, Aprile 25, 2024
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Cancer, RWE, EDT, Cancer Moonshot, Lung cancer, Hope, Nivolumab, American Urological Association, Second, Pembrolizumab, Survival, Immunotherapy, American Cancer Society, Webcast, BCG, Disease, Patient, Medicine, AUA, Multimedia, Death, NK, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240424428572/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240424428572/en/
    In NSCLC patients who relapsed or were refractory to checkpoint inhibitors, ANKTIVA was administered together with the same checkpoint inhibitor.
  • The addition of ANKTIVA resulted in the rescue of the checkpoint therapy efficacy, with significant prolongation of overall survival.
  • This prolongation of survival in NSCLC following checkpoint failure is consistent with ImmunityBio’s findings of durable complete responses following BCG failure in NMIBC.
  • According to the American Cancer Society, lung cancer is the second most common cancer in the U.S.